0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Highlight report: Cell type selection for toxicity testing

      editorial
      * , 1
      EXCLI Journal
      Leibniz Research Centre for Working Environment and Human Factors

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

           An important step in in vitro test system development is the choice of an adequate cell line which depends on the intended application of the assay. In a recent study, Tuuli Karhu and colleagues from Helsinki University compared a set of cell lines for their susceptibility towards eight GATA4 targeting compounds (Karhu et al., 2018[7]). GATA4 is a transcription factor involved in cardiac development (Gupta et al., 2013[6]; Kikuchi et al., 2010[8]; Rysä et al., 2010[15]; Pikkarainen et al., 2004[13]). The goal of the study was to identify which cell line allows the most sensitive cytotoxicity screening of these compounds. The tested cell lines included the myoblast cell line H9c2 established from rat myocardium; primary neonatal rat cardiac fibroblasts; mouse embryonic fibroblasts; mouse embryonic stem cells (mECSs), mouse embryonic stem cell derivatives from day 5 embryoid bodies; induced pluripotent human stem cells (hiPSC); and hiPSC-derived cardiomyocytes. The most susceptible cell lines towards the set of test compounds were hiPSC and mESC, while cardiomyocytes, fibroblasts and H9c2 cells were most resistant (Karhu et al., 2018[7]). Of course screening for the most sensitive cell line does not guarantee that the test cells will be most relevant for the human in vivo situation. However, if one is interested in a cytotoxicity screening system with the highest sensitivity, the recommendation of the authors to further use hiPSC seems reasonable. In recent years, the development of stem cell based test systems has been a major focus of research (Leist et al., 2017[10]; Godoy et al., 2013[3]; Krug et al., 2013[9]). The most frequently applied strategy is to expose stem cells to test compounds, when they differentiate to more mature cell types (Shinde et al., 2017[17]; Pallocca et al., 2016[12]). This approach has been used for developmental neurotoxicity (Waldmann et al., 2014[18]; Meganathan et al., 2015[11]; Weng et al., 2014[19]; Rempel et al., 2015[14]) and for cardiotoxicity (Chaudhari et al., 2016[1][2]; Sampaio et al., 2016[16]) testing. While tests that analyze the influence of compounds on the differentiation process are already successfully applied, it still remains a challenge to generate mature cell types, e.g. hepatocytes that closely resemble the primary cells in an adult organ (Godoy et al., 2016[5], 2018[4]). Although much progress has been achieved in stem cell based test system development, systematic analysis of human in vivo relevance still remains a major challenge.

          Related collections

          Most cited references17

          • Record: found
          • Abstract: found
          • Article: not found

          GATA transcription factors in the developing and adult heart.

          During the past decade, emerging evidence has accumulated of different nuclear transcription factors in regulation of cardiac development and growth as well as in cardiac hypertrophy and heart failure. GATA-4, -5 and -6 are zinc finger transcription factors that are expressed in the developing heart and GATA-4 and -6 continue expression in the adult cardiac myocytes. GATA-4 and -6 regulate expression of several cardiac-specific genes, and during murine embryonic development, GATA-4 is essential for proper cardiac morphogenesis. In support of this, mutations of gene for GATA-4 or for its cofactors have been associated with human congenital heart disease. Pressure overload of the heart in vivo as well as hypertrophic stimulation of cardiac myocytes in vitro provide adequate stimulus for activation of GATA-4. Activity of GATA-4 transcription factor is subject to regulation at the level of gene expression and through post-translational modifications of GATA-4 protein. A number of genes induced during cardiac hypertrophy possess functional GATA sites in their promoter region and cardiac-specific overexpression of GATA-4 or -6 leads to cardiac hypertrophy. In addition, a pattern of interactions between GATA-4 and its numerous cofactors have been identified, showing an increasing complexity in regulatory mechanisms. The present review discusses current evidence of the role and regulation of GATA transcription factors in the heart, with an emphasis in the GATA-4 and development of cardiac hypertrophy. Copyright 2004 European Society of Cardiology
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Adverse outcome pathways: opportunities, limitations and open questions.

            Adverse outcome pathways (AOPs) are a recent toxicological construct that connects, in a formalized, transparent and quality-controlled way, mechanistic information to apical endpoints for regulatory purposes. AOP links a molecular initiating event (MIE) to the adverse outcome (AO) via key events (KE), in a way specified by key event relationships (KER). Although this approach to formalize mechanistic toxicological information only started in 2010, over 200 AOPs have already been established. At this stage, new requirements arise, such as the need for harmonization and re-assessment, for continuous updating, as well as for alerting about pitfalls, misuses and limits of applicability. In this review, the history of the AOP concept and its most prominent strengths are discussed, including the advantages of a formalized approach, the systematic collection of weight of evidence, the linkage of mechanisms to apical end points, the examination of the plausibility of epidemiological data, the identification of critical knowledge gaps and the design of mechanistic test methods. To prepare the ground for a broadened and appropriate use of AOPs, some widespread misconceptions are explained. Moreover, potential weaknesses and shortcomings of the current AOP rule set are addressed (1) to facilitate the discussion on its further evolution and (2) to better define appropriate vs. less suitable application areas. Exemplary toxicological studies are presented to discuss the linearity assumptions of AOP, the management of event modifiers and compensatory mechanisms, and whether a separation of toxicodynamics from toxicokinetics including metabolism is possible in the framework of pathway plasticity. Suggestions on how to compromise between different needs of AOP stakeholders have been added. A clear definition of open questions and limitations is provided to encourage further progress in the field.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach

              Developmental neurotoxicity (DNT) and many forms of reproductive toxicity (RT) often manifest themselves in functional deficits that are not necessarily based on cell death, but rather on minor changes relating to cell differentiation or communication. The fields of DNT/RT would greatly benefit from in vitro tests that allow the identification of toxicant-induced changes of the cellular proteostasis, or of its underlying transcriptome network. Therefore, the ‘human embryonic stem cell (hESC)-derived novel alternative test systems (ESNATS)’ European commission research project established RT tests based on defined differentiation protocols of hESC and their progeny. Valproic acid (VPA) and methylmercury (MeHg) were used as positive control compounds to address the following fundamental questions: (1) Does transcriptome analysis allow discrimination of the two compounds? (2) How does analysis of enriched transcription factor binding sites (TFBS) and of individual probe sets (PS) distinguish between test systems? (3) Can batch effects be controlled? (4) How many DNA microarrays are needed? (5) Is the highest non-cytotoxic concentration optimal and relevant for the study of transcriptome changes? VPA triggered vast transcriptional changes, whereas MeHg altered fewer transcripts. To attenuate batch effects, analysis has been focused on the 500 PS with highest variability. The test systems differed significantly in their responses (<20 % overlap). Moreover, within one test system, little overlap between the PS changed by the two compounds has been observed. However, using TFBS enrichment, a relatively large ‘common response’ to VPA and MeHg could be distinguished from ‘compound-specific’ responses. In conclusion, the ESNATS assay battery allows classification of human DNT/RT toxicants on the basis of their transcriptome profiles. Electronic supplementary material The online version of this article (doi:10.1007/s00204-012-0967-3) contains supplementary material, which is available to authorized users.
                Bookmark

                Author and article information

                Journal
                EXCLI J
                EXCLI J
                EXCLI J
                EXCLI Journal
                Leibniz Research Centre for Working Environment and Human Factors
                1611-2156
                18 December 2018
                2018
                : 17
                : 1180-1181
                Affiliations
                [1 ]IfADo - Leibniz Research Centre for Working Environment and Human Factors, Dortmund, GERMANY
                Author notes
                *To whom correspondence should be addressed: H. M. Bolt, IfADo - Leibniz Research Centre for Working Environment and Human Factors, Dortmund, GERMANY, E-mail: bolt@ 123456ifado.de
                Article
                2018-2017 Doc1180
                10.17179/excli2018-2017
                6341425
                16f8d96d-e2a2-4ae7-854a-7d71d35cbb75
                Copyright © 2018 Bolt

                This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence ( http://creativecommons.org/licenses/by/4.0/) You are free to copy, distribute and transmit the work, provided the original author and source are credited.

                History
                : 17 December 2018
                : 18 December 2018
                Categories
                Editorial Material

                Comments

                Comment on this article